[Sánchez-Montalvá A, Salvador F, Espinosa-Pereiro J] Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Programa de salut internacional de l'Institut Català de la Salut (PROSICS), ICS, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Grupo de Estudio de micobacterias (GEIM), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC), Madrid, Spain. [Barios M, Lorenzo-Bosquet C] Servei de Medicina Nuclear, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Villar A] Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Tórtola T] Servei de Microbiologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Programa de salut internacional de l'Institut Català de la Salut (PROSICS), ICS, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Molina-Morant D, Molina I] Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Programa de salut internacional de l'Institut Català de la Salut (PROSICS), ICS, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2020-03-06T11:22:11Z
2020-03-06T11:22:11Z
2019-08-27
Tuberculosis; Positron emission tomography (PET); FDG
Tuberculosis; Tomografía por emisión de positrones (PET); FDG
Tuberculosi; Tomografia per emissió de positrons (PET); FDG
BACKGROUND: The aim of our study is to describe the FDG-PET/CT findings in patients with tuberculosis and to correlate them with the patient's prognosis. METHODS: We retrospectively collected data from patients with tuberculosis, who had an FDG-PET/CT performed prior to treatment initiation from 2010 to 2015. RESULTS: Forty-seven out of 504 patients with active tuberculosis diagnosis (9.33%) underwent an FDG-PET/CT. The reasons for performing the FDG-PET/CT were: characterization of a pulmonary nodule (24; 51.1%), study of fever of unknown origin (12; 25.5%), study of lymph node enlargement (5; 10.6%) and others (6; 12.8%). Median age was 64 (IQR 50-74) years and 31 (66%) patients were male. Twenty-six (55.3%) patients had an immunosuppressant condition. According to the FDG-PET/CT, 48.6% of the patients had more than 1 organ affected and 46.8% had lymph node involvement. Median SUVmax of the main lesion was 5 (IQR 0.28-11.85). We found an association between the FDG accumulation and the size of the main lesion with a correlation coefficient of 0.54 (p<0.002). Patients with an unsuccessful outcome had a higher ratio SUVmax main lesion / SUVmean liver (1.92 vs 7.67, p<0.02). CONCLUSIONS: In our cohort, almost half of the patients had more than 1 organ affected and 46.8% of them had lymph node involvement. FDG uptake was associated with the size of the main lesion and seems to be related to the treatment outcome. The extent of its potential to be used as an early predictor of treatment success still needs to be defined.
Article
Published version
English
Tuberculosi; Tomografia per emissió de positrons; Radiofàrmacs; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Image Interpretation, Computer-Assisted::Tomography, Emission-Computed::Positron-Emission Tomography::Positron Emission Tomography Computed Tomography; CHEMICALS AND DRUGS::Carbohydrates::Deoxy Sugars::Deoxyglucose::Fluorodeoxyglucose F18; DISEASES::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Positive Bacterial Infections::Actinomycetales Infections::Mycobacterium Infections::Tuberculosis; ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias grampositivas::infecciones por Actinomycetales::micobacteriosis::tuberculosis; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::interpretación de imágenes asistida por ordenador::tomografía computarizada radioisotópica::tomografía por emisión de positrones; COMPUESTOS QUÍMICOS Y DROGAS::hidratos de carbono::desoxiazúcares::desoxiglucosa::fluorodesoxiglucosa F18
Public Library Science
PLoS ONE;14(8)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0221516
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]